Tesamorelin

Nat Rev Drug Discov. 2011 Feb;10(2):95-6. doi: 10.1038/nrd3362.

Abstract

In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Publication types

  • News

MeSH terms

  • Abdominal Fat / drug effects
  • Abdominal Fat / metabolism
  • Animals
  • Clinical Trials as Topic / methods
  • Growth Hormone-Releasing Hormone / analogs & derivatives*
  • Growth Hormone-Releasing Hormone / pharmacokinetics
  • Growth Hormone-Releasing Hormone / therapeutic use*
  • HIV-Associated Lipodystrophy Syndrome / drug therapy*
  • HIV-Associated Lipodystrophy Syndrome / metabolism
  • Humans

Substances

  • Growth Hormone-Releasing Hormone
  • tesamorelin